Filip Mussen

1.6k total citations · 2 hit papers
10 papers, 1.0k citations indexed

About

Filip Mussen is a scholar working on Economics and Econometrics, Statistics and Probability and General Health Professions. According to data from OpenAlex, Filip Mussen has authored 10 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Economics and Econometrics, 3 papers in Statistics and Probability and 2 papers in General Health Professions. Recurrent topics in Filip Mussen's work include Health Systems, Economic Evaluations, Quality of Life (9 papers), Pharmaceutical Economics and Policy (4 papers) and Statistical Methods in Clinical Trials (3 papers). Filip Mussen is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (9 papers), Pharmaceutical Economics and Policy (4 papers) and Statistical Methods in Clinical Trials (3 papers). Filip Mussen collaborates with scholars based in United States, Belgium and Netherlands. Filip Mussen's co-authors include Kevin Marsh, Maarten J. IJzerman, Stuart Peacock, Rob Baltussen, Meindert Boysen, Nancy Devlin, John B. Watkins, Praveen Thokala, Zoltán Kaló and Sam Salek and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Value in Health and Pharmacoepidemiology and Drug Safety.

In The Last Decade

Filip Mussen

10 papers receiving 1.0k citations

Hit Papers

Multiple Criteria Decision Analysis for Health Care Decis... 2016 2026 2019 2022 2016 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force
    2016 444 citations Praveen Thokala, Nancy Devlin et al. Value in Health profile →
  2. Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force
    2016 301 citations Kevin Marsh, Maarten J. IJzerman et al. Value in Health profile →

Peers

Filip Mussen
Meindert Boysen United Kingdom
Diana Brixner United States
Amr Makady Netherlands
Gregory W. Daniel United States
Janine A. van Til Netherlands
Mitchell K. Higashi United States
P. R. Philips United Kingdom
Chris Henshall United Kingdom
Andrea Burton United Kingdom
Erin Holve United States
Meindert Boysen United Kingdom
Filip Mussen
Citations per year, relative to Filip Mussen Filip Mussen (= 1×) peers Meindert Boysen

Countries citing papers authored by Filip Mussen

Since Specialization
Citations

This map shows the geographic impact of Filip Mussen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filip Mussen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filip Mussen more than expected).

Fields of papers citing papers by Filip Mussen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Filip Mussen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filip Mussen. The network helps show where Filip Mussen may publish in the future.

Co-authorship network of co-authors of Filip Mussen

This figure shows the co-authorship network connecting the top 25 collaborators of Filip Mussen. A scholar is included among the top collaborators of Filip Mussen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filip Mussen. Filip Mussen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Thokala, Praveen, Nancy Devlin, Kevin Marsh, et al.. (2016). Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health. 19(1). 1–13. 444 indexed citations breakdown →
2.
Marsh, Kevin, Maarten J. IJzerman, Praveen Thokala, et al.. (2016). Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health. 19(2). 125–137. 301 indexed citations breakdown →
3.
Andrews, Elizabeth, et al.. (2010). Application of the BRAT Framework to Case Studies: Observations and Insights. Clinical Pharmacology & Therapeutics. 89(2). 217–224. 59 indexed citations
4.
Coplan, Paul, et al.. (2010). Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit–Risk Balance of Medicines. Clinical Pharmacology & Therapeutics. 89(2). 312–315. 93 indexed citations
5.
Mussen, Filip, Sam Salek, Stuart Walker, & Alasdair Breckenridge. (2010). Benefit-Risk Appraisal of Medicines: A Systematic Approach to Decision-making. Medical Entomology and Zoology. 25 indexed citations
6.
Stang, Paul, et al.. (2008). The Identification of Benefit in Medical Intervention: An Overview and Suggestions for Process. American Journal of Therapeutics. 15(5). 495–503. 5 indexed citations
7.
Mussen, Filip, et al.. (2008). Benefit‐Risk Appraisal of Medicines. 11 indexed citations
8.
Mussen, Filip, Sam Salek, & Stuart Walker. (2007). A quantitative approach to benefit-risk assessment of medicines – part 1: the development of a new model using multi-criteria decision analysis. Pharmacoepidemiology and Drug Safety. 16(S1). S2–S15. 92 indexed citations
9.
Mussen, Filip, Sam Salek, & Stuart Walker. (2007). A quantitative approach to benefit-risk assessment of medicines—part 1: the development of a new model using multi-criteria decision analysis; part 2: the practical application of a new model. Pharmacoepidemiology and Drug Safety. 16(S1). S42–S46. 10 indexed citations
10.
Mussen, Filip, Sam Salek, Stuart Walker, & Lawrence D. Phillips. (2007). A quantitative approach to benefit-risk assessment of medicines - part 2: the practical application of a new model (vol 16, pg S16, 2007). Digital Access to Libraries. 16(8). 946–946. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meindert Boysen Breakdown of academic impact, for papers by Diana Brixner Breakdown of academic impact, for papers by Amr Makady Breakdown of academic impact, for papers by Gregory W. Daniel Breakdown of academic impact, for papers by Janine A. van Til Breakdown of academic impact, for papers by Mitchell K. Higashi Breakdown of academic impact, for papers by P. R. Philips Breakdown of academic impact, for papers by Chris Henshall Breakdown of academic impact, for papers by Andrea Burton Breakdown of academic impact, for papers by Erin Holve
Rankless by CCL
2026